Royalty Pharma plc
RPRXNASDAQHealthcare● Active
$55.87
+$0.85(+1.54%)
Market Cap$24.0B
P/E Ratio—
52W High$56.07
52W Low$33.37
Royalty Pharma plc (RPRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RPRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$1.30
Est. $1.21 · +7.4%
Revenue
$0.93B
Est. $0.88B · +4.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
RPRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $1.27 | — | — | — | $0.79B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $1.21 | $1.30 | +7.4% | $0.93B | $0.88B | +4.9% |
| ▲ Q1 FY2026 | Feb 11, 2026 | $1.29 | $1.46 | +13.2% | $0.87B | $0.81B | +8.3% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.99 | $1.17 | +17.7% | $0.61B | $0.72B | -15.1% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $1.03 | $1.14 | +10.7% | $0.58B | $0.67B | -14.0% |
| ▲ Q2 FY2025 | May 8, 2025 | $0.95 | $1.06 | +11.2% | $0.57B | $0.71B | -19.4% |
| ▲ Q1 FY2025 | Feb 11, 2025 | $0.99 | $1.15 | +16.2% | $0.59B | $0.69B | -13.6% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.93 | $1.04 | +12.1% | $0.56B | $0.70B | -19.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$1.27
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$1.30
EPS Est.
$1.21
EPS Surpr.
+7.4%
Revenue
$0.93B
Q1 FY2026
Feb 11, 2026Beat
EPS Actual
$1.46
EPS Est.
$1.29
EPS Surpr.
+13.2%
Revenue
$0.87B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$1.17
EPS Est.
$0.99
EPS Surpr.
+17.7%
Revenue
$0.61B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$1.14
EPS Est.
$1.03
EPS Surpr.
+10.7%
Revenue
$0.58B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$1.06
EPS Est.
$0.95
EPS Surpr.
+11.2%
Revenue
$0.57B
Q1 FY2025
Feb 11, 2025Beat
EPS Actual
$1.15
EPS Est.
$0.99
EPS Surpr.
+16.2%
Revenue
$0.59B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$1.04
EPS Est.
$0.93
EPS Surpr.
+12.1%
Revenue
$0.56B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.66 | $1.73 | $1.85 | 1 |
| Q3 FY2027 | $1.25 | $1.31 | $1.40 | 1 |
| Q2 FY2027 | $1.43 | $1.49 | $1.60 | 1 |
| Q1 FY2027 | $1.26 | $1.32 | $1.41 | 1 |
| Q4 FY2026 | $1.43 | $1.50 | $1.61 | 1 |
| Q3 FY2026 | $1.11 | $1.13 | $1.15 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.0B | $1.0B | $1.0B | 1 |
| Q3 FY2027 | $0.9B | $1.0B | $1.0B | 1 |
| Q2 FY2027 | $0.8B | $0.9B | $0.9B | 1 |
| Q1 FY2027 | $0.9B | $1.0B | $1.0B | 1 |
| Q4 FY2026 | $0.9B | $0.9B | $1.0B | 1 |
| Q3 FY2026 | $0.9B | $0.9B | $0.9B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +7.4% | $50.44 | $50.72 | +0.56% |
| ▲ Q1 FY2026 | Feb 11, 2026 | +13.2% | $44.21 | $44.25 | +0.09% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +17.7% | $37.84 | $40.42 | +6.82% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +10.7% | $37.91 | $37.12 | -2.08% |
| ▲ Q2 FY2025 | May 8, 2025 | +11.2% | $32.75 | $33.10 | +1.07% |
| ▲ Q1 FY2025 | Feb 11, 2025 | +16.2% | $31.72 | $32.25 | +1.67% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +12.1% | $27.54 | $26.64 | -3.27% |
| ▲ Q3 FY2024 | Aug 8, 2024 | -0.5% | $27.25 | $26.15 | -4.04% |
Q2 FY2026+0.56%
Report Date
May 6, 2026
EPS Beat/Miss
+7.4%
Price Before
$50.44
Price After
$50.72
Q1 FY2026+0.09%
Report Date
Feb 11, 2026
EPS Beat/Miss
+13.2%
Price Before
$44.21
Price After
$44.25
Q4 FY2025+6.82%
Report Date
Nov 5, 2025
EPS Beat/Miss
+17.7%
Price Before
$37.84
Price After
$40.42
Q3 FY2025-2.08%
Report Date
Aug 6, 2025
EPS Beat/Miss
+10.7%
Price Before
$37.91
Price After
$37.12
Q2 FY2025+1.07%
Report Date
May 8, 2025
EPS Beat/Miss
+11.2%
Price Before
$32.75
Price After
$33.10
Q1 FY2025+1.67%
Report Date
Feb 11, 2025
EPS Beat/Miss
+16.2%
Price Before
$31.72
Price After
$32.25
Q4 FY2024-3.27%
Report Date
Nov 6, 2024
EPS Beat/Miss
+12.1%
Price Before
$27.54
Price After
$26.64
Q3 FY2024-4.04%
Report Date
Aug 8, 2024
EPS Beat/Miss
-0.5%
Price Before
$27.25
Price After
$26.15
Avg Beat Reaction+0.10%
Beat Rate8 / 8 quarters
Largest Move+6.82% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RPRX ends December
Royalty Pharma plc (RPRX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $1.30 — beating the analyst consensus of $1.21 by +7.4%. RPRX has beaten EPS estimates for 7 consecutive quarters. The next RPRX earnings date is expected around September 1, 2026.
Each quarter, investors track RPRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RPRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RPRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RPRX earnings · 5 questionsRoyalty Pharma plc's next earnings report is expected around September 1, 2026. RPRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RPRX historically reports after market close (AMC).
RPRX earnings datewhen is RPRX earningsRPRX next earnings datewhen does RPRX report earningsRPRX earnings calendar
▸ Source: FMP · Royalty Pharma plc SEC filings · US GAAP · Royalty Pharma plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026